BiotechTube
Autonomous Medical Devices

Autonomous Medical Devices

San Diego, United States· Est.
amdilabs.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

AMDI is a private, pre-revenue diagnostics company focused on revolutionizing infectious disease testing with its ultra-fast PCR platform. The company has submitted a dual 510(k) and CLIA Waiver application to the FDA for its Fast PCR Mini Respiratory Panel, aiming to enable molecular testing in primary care, urgent care, and retail clinics. Led by an experienced CEO with a track record of commercializing diagnostic platforms, AMDI's mission is to provide actionable, patient-centric results within minutes through a cloud-connected system.

Infectious Disease

Technology Platform

AMDI Fast PCR: A CLIA-waivable, sample-to-answer, cloud-connected molecular diagnostic platform designed to deliver PCR results for key pathogens in less than 10 minutes at the point of care.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive, growing trend toward decentralized care creates a strong demand for rapid, accurate diagnostics in non-lab settings like urgent care and retail clinics.
A successful CLIA Waiver would remove a major regulatory barrier to widespread adoption.
The platform's ultra-fast 10-minute PCR time could provide a significant competitive edge in clinical workflow integration.

Risk Factors

The company's viability is contingent on successful FDA 510(k) clearance and CLIA Waiver, with any delay or rejection posing an existential threat.
It faces intense competition from well-funded, established diagnostics companies in the point-of-care molecular space.
Commercializing a new hardware platform requires significant capital and execution skill to build sales, distribution, and market acceptance.

Competitive Landscape

AMDI competes in the rapid point-of-care molecular diagnostics market against large, established players like Abbott (ID NOW), Cepheid (GeneXpert), and bioMérieux/BioFire (FilmArray). These competitors have extensive installed bases, broad test menus, and strong commercial networks. AMDI's primary differentiation is its claimed speed (<10 minutes) and focus on CLIA-waivability for the broadest possible site placement.

More companies in Diagnostics & Precision Medicine →More companies in United States →